Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Krebs Biochem.&Inds
|
Bal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | 56.46 % | 1.96 % |
|
5yr average Equity Multiplier
|
3.77 | -2.97 | 4.59 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.3 | 0.98 |
|
5yr Avg Net Profit Margin
|
-36.55 % | -60.0 % | -0.04 % |
|
Price to Book
|
3.42 | 0.0 | 2.59 |
|
P/E
|
40.74 | 0.0 | 24.53 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | -861.42 Days | 41.77 Days |
|
Inventory Days
|
87.65 Days | 115.42 Days | 106.16 Days |
|
Days Receivable
|
132.64 Days | 8.79 Days | 104.16 Days |
|
Days Payable
|
210.48 Days | 408.94 Days | 132.37 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | -5.02 | 1.22 |
|
5yr Avg ROCE
|
-11.61 % | -22.06 % | 15.4 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | -38.55 % | 7.79 % |
|
5 yr average Debt to Equity
|
1.41 | -2.12 | 2.03 |
|
5yr CAGR Net Profit
|
12.0 % | -7.31 % | n/a |
|
5yr Average Return on Assets
|
-16.11 % | -17.59 % | 0.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 72.74 % | 50.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.42 % | 0.0 | 1.29 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharma
|
Krebs Biochem.&Inds
|
Bal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|